ENABLE BIOTECH

As a proud Swiss company, ENABLE BIOTECH celebrates Switzerland’s global reputation as a life science innovation hotspot. Besides well-known big pharma companies in Basel, Zurich, and Geneva, these cities are also rich clusters of growth for smaller biotechs and biopharma companies. Whether this is because of Switzerland’s central location in Europe, the presence of strong life science talent, or government investment in R&D, it looks like the growth will only continue. To us, this makes Switzerland a great place to get connected to in order to bring your new products across Europe. If you’re looking to break into the European market, why not consider manufacturing or running a First-in-Human trial in Switzerland? Or if you’re already based here, look no further! Let’s chat about how we could support. #biotech #biotechinnovation #lifescience #startups #biomanufacturing #biopharma #switzerland Map source Interpharma: https://lnkd.in/gaw5FSJf

Last week at the Festival of Biologics in Basel, Renaud JACQUEMART, PhD, MBA and Alain Pralong had the opportunity to connect with industry leaders and attend some truly insightful talks. A big thank you to the organizers Festival of Biologics for an excellent event! They also took advantage of being so close to the headquarter of Enable Biotech to meet with the rest of the team and discuss the exciting progress of the company.

ENABLE Biotech is looking forward to attending #festofbiologics in a couple weeks. Renaud and Alain from the team will be in Basel, always open to making new connections with companies developing advanced therapies (stem cell, exosome, gene-modified cell therapies, and more). Please reach out or stop by our booth S15 to learn more about ENABLE BIOTECH! Not planning to attend the conference? No worries, we can meet local companies at their offices or for a coffee during the week. About Terrapinn’s Festival of Biologics: The Festival of Biologics brings together pharma & biotech, academics, research institutes, regulators, patients groups and payers together with their partners across the value chain to bring you from discovery to market. The event features 150 leading solution providers to meet your needs across discovery, development, manufacturing, fill finish and market access. 15 – 17 October 2024 Hall 1, Messe Basel https://lnkd.in/gfgMHk4 #biomanufacturing #nextgenCDMO #CDMO #ATMPs #celltherapy #cellandgene #exosomes #exosometherapy #startups 

While research studying the small vesicles released from cells that would later be called exosomes began in the 1960s, there were many years of ups and downs in the development of exosome therapies ready for clinical trials, including researching their potential therapeutic use, and addressing manufacturing challenges such as isolating them from cells. Indeed, the field continues to evolve, with the first exosome therapy approval becoming a promising opportunity with >40 exosome therapies in clinical trials as of 2022. #exosometherapies #ATMPs #nextgenCDMO #CDMO #biomanufacturing #biotechinnovation #biotech #biopharma

CAR-NK cells are emerging as a powerful advancement in CAR therapies which have been used commercially for several years. CAR-NK therapy leverages the natural ability of NK cells to target and eliminate abnormal cells, including tumors.    Here’s why this this novel therapy is gaining traction:    1.  Enhanced Safety: CAR-NK cells have a lower risk of causing severe immune side effects compared to CAR-T cells, making them a safer option for patients.  2.  Efficient Antitumor Activity: CAR-NK therapies have shown strong anti-tumor responses in clinical trials, making them a powerful therapy against both solid tumors and hematological malignancies.  3.  Broad Immunity: CAR-NK therapies target a broader variety of abnormal cell types due to their natural tumor-targeting capabilities, whereas CAR-T therapies are typically designed to target specific antigens present on cancer cells.   4.  Potential for Allogeneic Therapies: Unlike CAR-T, which is often patient-specific, CAR-NK cells can be produced from diverse sources such as umbilical cord blood and NK cell lines, allowing for faster, more scalable production.    With these advantages, CAR-NK therapies are poised to complement and perhaps even surpass CAR-T therapies in the fight against cancer. At ENABLE Biotech, we are equipped to support companies developing these and other innovative treatments. #CellTherapy #CARNK #Biotech #Innovation #CancerTherapy #CDMO #Manufacturing  #ATMPs #NKcelltherapy #Biotechinnovation #nextgenCDMO #biomanufacturing

Exosome therapies are a new modality of ATMPs, for which no therapy has yet been commercially approved, despite several ongoing clinical trials. Exosome therapy has diverse applications:   1.    In regenerative medicine, exosomes support tissue repair in conditions like liver fibrosis and spinal cord injury. 2.    They enable targeted drug delivery by transporting therapeutic agents, such as siRNA, across the blood-brain barrier. 3.    Exosomes from mesenchymal stem cells offer immunomodulatory and anti-inflammatory effects, making them promising for cancer and gene therapy. 4.    Diagnostic use includes evaluating exosome contents in biological samples for cancer diagnosis through liquid biopsy.   At ENABLE Biotech, we have expertise and available capacity to manufacture exosome therapies as well as other advanced therapies, and our network of experts understands the unique CMC considerations for this new technology.   #exosometherapies #advancedtherapies #CMC #CDMO #biomanufacturing #biotechinnovation #ATMPs

Choosing the right gene modification method—whether vectors, pDNA, or electroporation—is crucial for the success of gene-modified cell therapies. Here are five key factors to consider: 1. Therapeutic Goals: Align the choice of method with your therapeutic objectives, whether it's correcting a gene mutation, enhancing cell functionality, or performing complex gene edits. 2. Safety Profile: Patient safety is paramount. Evaluate the risks, such as off-target effects and immune responses, ensuring the method chosen offers a favorable safety profile. 3. Efficiency and Precision: Select a method that ensures high transfection efficiency and precise gene modifications with minimal off-target effects to maximize therapeutic efficacy. 4. Scalability and Reproducibility: Consider the method's ability to scale for large-scale production and its reproducibility to ensure consistent results across batches. 5. Regulatory Compliance: Ensure the method meets regulatory requirements. Understanding the regulatory landscape and adhering to guidelines is essential for a smooth approval process. At ENABLE BIOTECH, we provide a network of experts who have worked with each method of gene modification, helping sponsors navigate critical considerations in the development of safe, effective, and scalable gene-modified cell therapies. #AdvancedTherapy #CellTherapy #Biotech #GeneEditing #Innovation #Healthcare #CDMO #nextgenCDMO 

Today, we celebrate the beauty and spirit of Switzerland with its breathtaking landscapes, delicious chocolate, and rich traditions. Switzerland is also leading in developing innovative CGT in Europe. Happy Swiss National Day, everyone! 🇨🇭🎇 #SwissNationalDay #CelebrateSwitzerland #ProudlySwiss

It may seem obvious that different drug modalities require different manufacturing processes. Cell therapies use or modify whole living cells, biologics are single active large molecules produced by cell expression systems, and small molecule drugs are chemically synthesized. Some CDMOs try to do it all, despite technical differences. When working with different modalities, it is very important to choose a CDMO with the specific expertise and a focus on your type of technology to ensure they have an understanding of the nuances of your manufacturing process. ENABLE Biotech is specifically focused on the manufacturing of stem, cell, and exosome therapies in order to offer Sponsors the expertise needed from development to First-in-Human stages. Our team is strengthened by the expertise of our founder Alain Pralong, who has been working on cell therapies since their inception.   #CDMOs #advancedmanufacturing #nextgenerationCDMO #ATMPs #celltherapy #exosometherapy #CGT

You may be wondering why ENABLE Biotech calls themselves a next-generation CDMO. We use this term because we are focused on a novel operating model, tailored to the unique needs of ATMP startups and spinouts. Our unique operating model is based on 5 differentiating factors: 1.  CMC Expertise: in-house specific cell & exosome therapy expertise to support with preparation of dossier sections for CTA/IND submission and considering scale-up requirements for manufacturing processes 2. Collaborative Tech Transfer Process: option for Sponsors to visit our manufacturing site in-person and work with our team in the lab to guarantee a smooth tech transfer process 3. Novel Pricing Model: affordable pricing alleviating fundraising pressure to FIH trials for early-stage companies  4. On-Demand Expertise: access to highly qualified people to support the product development, regulatory, and quality assurance processes on-demand 5. Vendor Qualification: leverage our network of vendors that have already been evaluated and validated for activities requiring outsourcing If you’re curious and would like more details about our next-generation CDMO, feel free to reach out to us! Alain Pralong Renaud JACQUEMART, PhD, MBA Geraldine Guenot Katrina Cordovado, MBDC #NextgenerationCDMO #CDMO #ATMPs #CellTherapy #ExosomeTherapy #Startups